Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03954639
Other study ID # 402-C-332
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date June 15, 2020
Est. completion date September 2020

Study information

Verified date May 2020
Source Pacira Pharmaceuticals, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 3, multicenter, randomized, double blinded, active controlled study in approximately 81 subjects undergoing lower extremity surgeries with combined sciatic and adductor canal nerve block.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 2020
Est. primary completion date September 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Healthy adult male or female volunteers ages 18 or older

2. American Society of Anesthesiologists (ASA) physical status 1, 2 or 3.

3. Able to provide informed consent, adhere to the study schedule, and complete all study assessments.

4. Body Mass Index =18 and =40 kg/m2

Exclusion Criteria:

1. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications for which an alternative is not named in the protocol (eg, amide-type local anesthetics, opioids, bupivacaine, NSAIDs)

2. Documented history of long-term diabetes, renal (serum creatinine level >2mg/dL [176.8 µmol/L]) or hepatic dysfunction (serum alanine or aspartame transferase > 3 times the upper limit of normal), coagulation or bleeding disorder and severe peripheral vascular disease

3. Concurrent painful physical condition that may require analgesic treatment (such as long-term, consistent use of opioids) in the post dosing period for pain and which, in the investigator's opinion may confound the post dosing assessments

4. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years

5. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study

6. Previous participation in EXPAREL study

7. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, could interfere with study assessments or compliance

8. Currently pregnant, nursing, or planning to become pregnant during the study

9. Clinically significant medical disease that, in the opinion of the investigator, would make participation in a clinical study inappropriate. This includes any psychiatric or other conditions that would constitute a contraindication to participation in the study

10. Currently on neuroleptic agent [e.g., gabapentin, pregabalin (Lyrica), duloxetine (Cymbalta) etc.]

11. Inadequate sensory function on the foot (monofilament test)

12. Chronic opioid use in the last 30 days (=30 morphine equivalents/ day)

In addition, the subject may be withdrawn from the study if the subject meets the following criterion during or post-surgery:

13. Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that, in the opinion of the investigator, renders the subject medically unstable or complicates the subject's post-operative course

Study Design


Intervention

Drug:
EXPAREL 13.3Mg/mL Suspension for Injection
Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)
Bupivacaine Hydrochloride
Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Pacira Pharmaceuticals, Inc

Outcome

Type Measure Description Time frame Safety issue
Primary Magnitude of analgesic effect Area under the Curve of the NRS Pain intensity scores from 0 hours to 96 hours post-surgery. 0 hours to 96 hours
Secondary Total Postsurgical Opioid Consumption Total Postsurgical opioid consumption from 0 hours to 96 hours post-surgery 0 hours to 96 hours
See also
  Status Clinical Trial Phase
Completed NCT01435577 - Intravenous Tapentadol in Post-Bunionectomy Pain Phase 2
Terminated NCT05082012 - Early Weight-Bearing After the Lapiplasty Mini-Incision Procedure (Mini3D) N/A
Terminated NCT03257540 - Early Weight-Bearing After Lapidus Arthrodesis
Completed NCT04518462 - Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries Phase 3
Completed NCT04084262 - Multi-Plane Hallux Valgus Correction With the Phantom® Nail
Active, not recruiting NCT03740282 - Early Weight-Bearing After the Lapiplasty Procedure N/A
Completed NCT01743625 - Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain Phase 3
Completed NCT01484652 - Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension Phase 3
Recruiting NCT05831449 - CPL-01 in the Management of Postoperative Pain After Bunionectomy Phase 3
Terminated NCT01133639 - Ketorolac Effects on Post-operative Pain and Bone Healing N/A
Completed NCT04826328 - Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy Phase 1
Recruiting NCT05773846 - A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical Pain Phase 3
Completed NCT03653429 - Efficacy of Tranexamic Acid in Foot and Ankle Surgeries Phase 4
Recruiting NCT04751344 - Liposomal Bupivacaine Versus Bupivacaine Plain for Operative Pain Management of Forefoot Surgery Phase 4
Completed NCT04002089 - Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy Phase 1
Terminated NCT02499575 - Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures N/A
Completed NCT00613938 - A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy. Phase 3
Completed NCT03246971 - Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain Phase 2
Completed NCT00890682 - Study of Postoperative Analgesia in Bunionectomy Phase 3
Active, not recruiting NCT05602844 - Clinical Trial on Patient-Specific-Instrumentation Assisted Lapidus Fusion for Hallux Valgus N/A